Table 1.
Baseline characteristics of patients with HCM at CMR1 and CMR2
| CMR 1 (n = 72) | CMR 2 (n = 72) | P-value | |
|---|---|---|---|
| Age (years) | 45 ± 12 | 51 ± 12 | <0.001 |
| Male, % (n) | 68 (49) | 68 (49) | 1.00 |
| Body mass index (kg/m2) | 27 ± 5 | 27 ± 5 | 0.08 |
| Hypertension, % (n) | 10 (7) | 11 (8) | 1.00 |
| Diabetes, % (n) | 3 (2) | 6 (4) | 0.68 |
| Smoker, % (n) | 7 (5) | 6 (4) | 1.00 |
| Atrial fibrillation, % (n) | 7 (5) | 10 (7) | 0.76 |
| SCD risk | |||
| Family history of SCD, % (n) | 26 (19) | 26 (19) | 1.00 |
| Unexplained syncope, % (n) | 4 (3) | 4 (3) | 1.00 |
| NSVT on Holter monitor, % (n) | 10 (7) | 24 (17) | 0.04 |
| Abnormal exercise BP response, % (n) | 1 (1) | 3 (2) | 1.00 |
| Maximum LV wall thickness ≥30 mm, % (n) | 4 (3) | 4 (3) | 1.00 |
| LV outflow tract gradient, % (n) | 15 (11) | 15 (11) | 1.00 |
| NYHA Class I, II, III, IV, % (n) | 82, 14, 4, 0 (59, 10, 3, 0) | 67, 25, 8, 0 (48, 18, 6, 0) | 0.11 |
| ESC risk score | 2.01 ± 0.86 | 2.31 ± 1.44 | 0.01 |
| SCD risk factors (0/1/2/3 risk factors), % (n) | 61, 33, 6, 0 (44, 24, 4, 0) | 47, 46, 6, 1 (34, 33, 4, 1) | 0.29 |
| Medications | |||
| β-Blockers, % (n) | 50 (36) | 65 (47) | 0.06 |
| Calcium channel blockers, % (n) | 8 (6) | 17 (12) | 0.27 |
| Disopyramide, % (n) | 6 (4) | 15 (11) | 0.09 |
| ACEI/ARB, % (n) | 14 (10) | 14 (10) | 1.00 |
| Diuretics, % (n) | 6 (4) | 7 (5) | 1.00 |
| Aspirin, % (n) | 25 (18) | 47 (34) | 0.006 |
| Warfarin, % (n) | 6 (4) | 11 (8) | 0.36 |
| CMR findings | |||
| LVEF (%) | 67 ± 6 | 67 ± 7 | 0.44 |
| LVEDV (mL) | 152 ± 30 | 155 ± 32 | 0.12 |
| LVEDV index (mL/m2) | 79 ± 14 | 79 ± 14 | 0.43 |
| LVESV (mL) | 51 ± 15 | 51 ± 18 | 0.67 |
| LA diameter (in LVOT/three-chamber view) | 37 ± 6 | 37 ± 7 | 0.37 |
| Stroke volume (mL) | 101 ± 19 | 104 ± 20 | 0.11 |
| LV mass (g) | 146 ± 52 | 151 ± 52 | 0.02 |
| LV mass index (g/m2) | 75 ± 25 | 76 ± 27 | 0.15 |
| Max LVWT(mm) | 19 ± 6 | 19 ± 5 | 0.79 |
| Presence of LGE, % (n) | 75 (54) | 82 (59) | 0.31 |
Data are represented as mean ± standard deviation.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; EDV, end-diastolic volume; EF, ejection fraction; ESC, European Society of Cardiology; ESV, end-systolic volume; HCM, hypertrophic cardiomyopathy; LA, left atrial; LGE, late gadolinium enhancement (5-SD); LV, Left ventricular; LVOT, left ventricular outflow tract; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; WT, wall thickness.